ClinicalTrials.gg
RecruitingNCT07772531Updated Nov 18, 2026

A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder

A Phase 2 interventional study of BMS-986511 and Placebo in Major Depressive Disorder, sponsored by Bristol-Myers Squibb. Recruiting at 24 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 257 under way, 26 of them phase 3. Depressive Disorder, Major · United States.

Planned enrollment
355th of 1,323
200 · median 70
Started
2026
with 81 others
Phase 2
271 of 1,500
45 open now
Primary completion
2028-11
later than 193 of 256 live
Registered
1,478th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 355th largest by planned enrollment of the 1,323 interventional ones that give a count, is one of 82 that started in 2026, is one of 271 in phase 2, reaches primary completion later than 193 of the 256 other live ones, and was the 1,478th registered.

Depressive Disorder, Major

3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

209 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 297 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

A Study to Evaluate BMS-986511 in Adults with Major Depressive Disorder

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder
  • Depression
  • BMS-986511
  • Evifacotrep
  • TRPC4/5 Inhibitor
  • Antidepressant
  • Mood Disorders
  • Central Nervous System
  • MDD
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet the MDD diagnosis per criteria confirmed by structured interview.
  • Participant must have current moderate to severe MDE confirmed by clinical assessment and validated scale.
  • Participant must have current MDE duration >12 weeks at screening.
  • Outpatient participants able to comply with study procedures.
  • Participant require medication washout completed before baseline.
  • Participant must have within protocol range.
  • Participants must meet reproductive safety requirements.

Exclusion criteria

Exclusion Criteria:

  • Participants must not have other primary psychiatric disorders or a history of treatment-resistant depression during the current episode.
  • Participants must not have recent history of active suicidal ideation or attempt within the past year.
  • Participants must not have prior lifetime treatment with electroconvulsive therapy, ketamine/esketamine, deep brain stimulation, or transcranial magnetic stimulation.
  • Participants must not have recent history of alcohol/substance abuse or use of cannabis.
  • Participants must not have significant abnormalities, or poorly controlled diabetes.
  • Other protocol defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    BMS-986511: Dose A

    Drug: BMS-986511

  • Experimental
    BMS-986511: Dose B

    Drug: BMS-986511

  • Experimental
    Placebo

    Drug: Placebo

Interventions

  • DrugBMS-986511

    Specified dose on specified days

    Also known as: Evifacotrep

  • DrugPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in Hamilton Depression Rating Scale -17 Item (HDRS-17) total score

    Time frame: Up to Day 57

Secondary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (AEs)

    Time frame: Up to 71 days

  2. Number of Participants with Serious Adverse Events (SAEs)

    Time frame: Up to 71 days

  3. Number of Participants with AEs Leading to Treatment Discontinuation

    Time frame: Up to 71 days

  4. Number of Participants with AEs Leading to Death

    Time frame: Up to Day 71

07

Study locations

3 of 24 sites recruiting
  • Local Institution - 0144
    Phoenix, Arizona 85012, United States
    Not yet recruiting
    • Site 0144 · Contact
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
    Recruiting
    • George Konis, Site 0038 · Contact501-221-8681
  • Woodland Research Northwest LLC
    Rogers, Arkansas 72758, United States
    Recruiting
    • Ryan Mahelona, Site 0047 · Contact479-927-3000
  • Local Institution - 0046
    Garden Grove, California 92845, United States
    Not yet recruiting
    • Site 0046 · Contact
  • Local Institution - 0042
    Glendale, California 91206, United States
    Not yet recruiting
    • Site 0042 · Contact
  • Local Institution - 0071
    Lemon Grove, California 91945, United States
    Not yet recruiting
    • Site 0071 · Contact
  • Local Institution - 0079
    Oakland, California 94607, United States
    Not yet recruiting
    • Site 0079 · Contact
  • Local Institution - 0050
    Upland, California 91786, United States
    Not yet recruiting
    • Site 0050 · Contact
  • Local Institution - 0007
    Jacksonville, Florida 32256, United States
    Not yet recruiting
    • Site 0007 · Contact
  • Local Institution - 0024
    Orlando, Florida 32801, United States
    Not yet recruiting
    • Site 0024 · Contact
  • CenExel CBH
    Atlanta, Georgia 30331, United States
    Recruiting
    • Elyssa Barron, Site 0140 · Contact404-881-5800
  • Local Institution - 0044
    Gaithersburg, Maryland 20877, United States
    Not yet recruiting
    • Site 0044 · Contact
  • Local Institution - 0041
    Cedarhurst, New York 11516, United States
    Not yet recruiting
    • Site 0041 · Contact
  • Local Institution - 0069
    Mount Kisco, New York 10549, United States
    Not yet recruiting
    • Site 0069 · Contact
  • Local Institution - 0121
    Staten Island, New York 10314, United States
    Not yet recruiting
    • Site 0121 · Contact
  • Local Institution - 0086
    Columbus, Ohio 43210, United States
    Not yet recruiting
    • Site 0086 · Contact
  • Local Institution - 0027
    Oklahoma City, Oklahoma 73116, United States
    Not yet recruiting
    • Site 0027 · Contact
  • Local Institution - 0003
    Everett, Washington 98201, United States
    Not yet recruiting
    • Site 0003 · Contact
  • Local Institution - 0080
    Prague, Czech Republic 10000, Czechia
    Not yet recruiting
    • Site 0080 · Contact
  • Local Institution - 0111
    Prague, Praha 6 16000, Czechia
    Not yet recruiting
    • Site 0111 · Contact
  • Local Institution - 0032
    Prague, Praha 8 18600, Czechia
    Not yet recruiting
    • Site 0032 · Contact
  • Local Institution - 0005
    Kladno, 27201, Czechia
    Not yet recruiting
    • Site 0005 · Contact
  • Local Institution - 0081
    Klecany, 25067, Czechia
    Not yet recruiting
    • Site 0081 · Contact
  • Local Institution - 0028
    Pilsen, 31200, Czechia
    Not yet recruiting
    • Site 0028 · Contact
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Nov 2028, 24 months after the start.

Of 98 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's planned 24 months is above that.

Counting every sponsor, half of 197 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2026
First posted
Aug 19, 2026
StartActual
Oct 30, 2026
Primary completionEst.
Nov 6, 2028
CompletionEst.
Nov 6, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 18, 2026
Sites
3 sites added, 6 sites removed. 21 sites changed recruiting status (21 now not yet recruiting)
Show 21 sites
  • Local Institution - 0144 · Phoenix, United Statesno status→Not yet recruiting
  • Local Institution - 0046 · Garden Grove, United Statesno status→Not yet recruiting
  • Local Institution - 0042 · Glendale, United Statesno status→Not yet recruiting
  • Local Institution - 0071 · Lemon Grove, United Statesno status→Not yet recruiting
  • Local Institution - 0079 · Oakland, United Statesno status→Not yet recruiting
  • Local Institution - 0050 · Upland, United Statesno status→Not yet recruiting
  • Local Institution - 0007 · Jacksonville, United Statesno status→Not yet recruiting
  • Local Institution - 0024 · Orlando, United Statesno status→Not yet recruiting
  • Local Institution - 0044 · Gaithersburg, United Statesno status→Not yet recruiting
  • Local Institution - 0041 · Cedarhurst, United Statesno status→Not yet recruiting
  • Local Institution - 0069 · Mount Kisco, United Statesno status→Not yet recruiting
  • Local Institution - 0121 · Staten Island, United Statesno status→Not yet recruiting
  • Local Institution - 0086 · Columbus, United Statesno status→Not yet recruiting
  • Local Institution - 0027 · Oklahoma City, United Statesno status→Not yet recruiting
  • Local Institution - 0003 · Everett, United Statesno status→Not yet recruiting
  • Local Institution - 0080 · Prague, Czechiano status→Not yet recruiting
  • Local Institution - 0111 · Prague, Czechiano status→Not yet recruiting
  • Local Institution - 0032 · Prague, Czechiano status→Not yet recruiting
  • Local Institution - 0005 · Kladno, Czechiano status→Not yet recruiting
  • Local Institution - 0081 · Klecany, Czechiano status→Not yet recruiting
  • Local Institution - 0028 · Pilsen, Czechiano status→Not yet recruiting
Show 3 added (3 United States)
  • Woodland International Research Group · Little Rock, United States
  • Woodland Research Northwest LLC · Rogers, United States
  • CenExel CBH · Atlanta, United States
Show 6 removed
  • Local Institution - 0038 · Little Rock, United States
  • Local Institution - 0047 · Rogers, United States
  • Local Institution - 0140 · Atlanta, United States
  • Local Institution - 0075 · Boston, United States
  • Local Institution - 0083 · Cincinnati, United States
  • Local Institution - 0016 · Dallas, United States
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Recruiting
    3 sites added, 6 sites removed. 21 sites changed recruiting status (21 now not yet recruiting)
    Show 21 sites
    • Local Institution - 0144 · Phoenix, United Statesno status→Not yet recruiting
    • Local Institution - 0046 · Garden Grove, United Statesno status→Not yet recruiting
    • Local Institution - 0042 · Glendale, United Statesno status→Not yet recruiting
    • Local Institution - 0071 · Lemon Grove, United Statesno status→Not yet recruiting
    • Local Institution - 0079 · Oakland, United Statesno status→Not yet recruiting
    • Local Institution - 0050 · Upland, United Statesno status→Not yet recruiting
    • Local Institution - 0007 · Jacksonville, United Statesno status→Not yet recruiting
    • Local Institution - 0024 · Orlando, United Statesno status→Not yet recruiting
    • Local Institution - 0044 · Gaithersburg, United Statesno status→Not yet recruiting
    • Local Institution - 0041 · Cedarhurst, United Statesno status→Not yet recruiting
    • Local Institution - 0069 · Mount Kisco, United Statesno status→Not yet recruiting
    • Local Institution - 0121 · Staten Island, United Statesno status→Not yet recruiting
    • Local Institution - 0086 · Columbus, United Statesno status→Not yet recruiting
    • Local Institution - 0027 · Oklahoma City, United Statesno status→Not yet recruiting
    • Local Institution - 0003 · Everett, United Statesno status→Not yet recruiting
    • Local Institution - 0080 · Prague, Czechiano status→Not yet recruiting
    • Local Institution - 0111 · Prague, Czechiano status→Not yet recruiting
    • Local Institution - 0032 · Prague, Czechiano status→Not yet recruiting
    • Local Institution - 0005 · Kladno, Czechiano status→Not yet recruiting
    • Local Institution - 0081 · Klecany, Czechiano status→Not yet recruiting
    • Local Institution - 0028 · Pilsen, Czechiano status→Not yet recruiting
    Show 3 added (3 United States)
    • Woodland International Research Group · Little Rock, United States
    • Woodland Research Northwest LLC · Rogers, United States
    • CenExel CBH · Atlanta, United States
    Show 6 removed
    • Local Institution - 0038 · Little Rock, United States
    • Local Institution - 0047 · Rogers, United States
    • Local Institution - 0140 · Atlanta, United States
    • Local Institution - 0075 · Boston, United States
    • Local Institution - 0083 · Cincinnati, United States
    • Local Institution - 0016 · Dallas, United States
    + 3 other changes: verification date, date precision and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07772531
Responsible party
Sponsor
First posted
Aug 19, 2026
Start date
Oct 30, 2026
Primary completion
Nov 6, 2028 (estimated)
Completion
Nov 6, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion